News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
石藥(01093.HK)安尼妥單抗聯合注射用多西他賽臨床結果於美國ASCO以LBA口頭報告形式呈列
石藥(01093.HK)公布，其附屬上海津曼特生物科技與康寧傑瑞合作開發的HER2雙特異性抗體安尼妥單抗(商品名：恩尼妥)(KN 026)聯合集團自主研發的注射用多西他賽(白蛋白結合型)(HB1801)新輔助治療HER2陽性乳腺癌的III期臨床研究(研究編號：KN026–004/Neo-Healer）之結果，已於2026年美國臨床腫瘤學會(ASCO)年會上以...
Reset
Send
The window will close in 5 seconds
石藥(01093.HK)安尼妥單抗聯合注射用多西他賽臨床結果於美國ASCO以LBA口頭報告形式呈列
Close
Recommend
13
Positive
19
Negative
4
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

石藥(01093.HK)  0.000 (0.000%)    Short selling $147.35M; Ratio 24.768%   公布，其附屬上海津曼特生物科技與康寧傑瑞合作開發的HER2雙特異性抗體安尼妥單抗(商品名：恩尼妥)(KN 026)聯合集團自主研發的注射用多西他賽(白蛋白結合型)(HB1801)新輔助治療HER2陽性乳腺癌的III期臨床研究(研究編號：KN026–004/Neo-Healer）之結果，已於2026年美國臨床腫瘤學會(ASCO)年會上以最新突破性摘要(LBA)口頭報告形式呈列。(jl/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-04 16:25.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.